Focused On-demand Library for Eukaryotic initiation factor 4A-II

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q14240

UPID:
IF4A2_HUMAN

ALTERNATIVE NAMES:
ATP-dependent RNA helicase eIF4A-2

ALTERNATIVE UPACC:
Q14240; D3DNU9; Q53XJ6; Q96B90; Q96EA8

BACKGROUND:
The ATP-dependent RNA helicase eIF4A-2, also known as Eukaryotic initiation factor 4A-II, is a key subunit of the eIF4F complex involved in mRNA cap recognition and binding to the ribosome. It is essential for unwinding RNA secondary structures in the 5'-UTR of mRNAs, a critical step for efficient binding of the small ribosomal subunit and subsequent scanning for the initiator codon, highlighting its significance in the translation initiation mechanism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Eukaryotic initiation factor 4A-II presents a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8358 of 8789